Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Proteinuria in children with autosomal dominant polycystic kidney disease.

Seeman T, Pohl M, John U.

Minerva Pediatr. 2018 Oct;70(5):413-417. doi: 10.23736/S0026-4946.16.04404-2.

PMID:
30302987
2.

Profiling proteinuria in children after renal transplantation.

Seeman T, Dusek J, Vondrák K, Spatenka J, Feber J.

Pediatr Nephrol. 2009 Dec;24(12):2439-44. doi: 10.1007/s00467-009-1275-x. Epub 2009 Aug 6.

PMID:
19657680
3.
4.

Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.

Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G; SIRENA 2 Study Group.

Clin J Am Soc Nephrol. 2016 May 6;11(5):785-94. doi: 10.2215/CJN.09900915. Epub 2016 Feb 22.

5.

Early renal abnormalities in children with postnatally diagnosed autosomal dominant polycystic kidney disease.

Selistre L, de Souza V, Ranchin B, Hadj-Aissa A, Cochat P, Dubourg L.

Pediatr Nephrol. 2012 Sep;27(9):1589-93. doi: 10.1007/s00467-012-2192-y. Epub 2012 Jun 12.

PMID:
22689086
6.

Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease.

Helal I, Reed B, McFann K, Yan XD, Fick-Brosnahan GM, Cadnapaphornchai M, Schrier RW.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2439-43. doi: 10.2215/CJN.01010211. Epub 2011 Sep 8.

7.

Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.

Raina R, Lou L, Berger B, Vogt B, Do AS, Cunningham R, Vasavada P, Herrmann K, Dell K, Simonson M.

BMC Nephrol. 2016 Feb 29;17:22. doi: 10.1186/s12882-016-0232-8.

8.

Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.

Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT.

Am J Kidney Dis. 2010 Nov;56(5):883-95. doi: 10.1053/j.ajkd.2010.06.023.

PMID:
20888104
9.

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.

Gansevoort RT, Meijer E, Chapman AB, Czerwiec FS, Devuyst O, Grantham JJ, Higashihara E, Krasa HB, Ouyang J, Perrone RD, Torres VE; TEMPO 3:4 Investigators.

Nephrol Dial Transplant. 2016 Nov;31(11):1887-1894. Epub 2015 Dec 17.

PMID:
26681730
10.

Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.

Spithoven EM, Meijer E, Boertien WE, Sinkeler SJ, Tent H, de Jong PE, Navis G, Gansevoort RT.

Am J Kidney Dis. 2013 Sep;62(3):531-40. doi: 10.1053/j.ajkd.2013.03.030. Epub 2013 May 25.

PMID:
23714171
11.

Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis.

Marlais M, Cuthell O, Langan D, Dudley J, Sinha MD, Winyard PJ.

Arch Dis Child. 2016 Dec;101(12):1142-1147. doi: 10.1136/archdischild-2015-310221. Epub 2016 Jun 10. Review.

PMID:
27288429
12.

The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease.

Tokiwa S, Muto S, China T, Horie S.

Clin Exp Nephrol. 2011 Aug;15(4):539-45. doi: 10.1007/s10157-011-0428-y. Epub 2011 Mar 24.

PMID:
21431900
13.

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators.

Clin J Am Soc Nephrol. 2016 May 6;11(5):803-11. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23.

14.
15.

[Blood pressure, functional and morphological study of kidneys in children with autosomal dominant polycystic kidney disease].

Seeman T, Vondrichová H, Strízová J, Sikut M, Janda J, Schärer K.

Cas Lek Cesk. 1999 Mar 15;138(6):178-84. Czech.

PMID:
10510532
16.

Albuminuria, Proteinuria, and Renal Disease Progression in Children with CKD.

Fuhrman DY, Schneider MF, Dell KM, Blydt-Hansen TD, Mak R, Saland JM, Furth SL, Warady BA, Moxey-Mims MM, Schwartz GJ.

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):912-920. doi: 10.2215/CJN.11971116. Epub 2017 May 25.

17.

Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.

Sans L, Radosevic A, Quintian C, Montañés R, Gràcia S, Vilaplana C, Mojal S, Ballarin JA, Fernández-Llama P, Torra R, Pascual J.

PLoS One. 2017 Mar 27;12(3):e0174583. doi: 10.1371/journal.pone.0174583. eCollection 2017.

18.

Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease.

Wong H, Vivian L, Weiler G, Filler G.

Am J Kidney Dis. 2004 Apr;43(4):624-8.

PMID:
15042539
19.

Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group.

Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME.

J Am Soc Nephrol. 1995 Jun;5(12):2037-47. Erratum in: J Am Soc Nephrol 1995 Oct;6(4):1318.

20.

The role of albuminuria in the follow-up of HIV-infected pediatric patients.

Deyà-Martínez A, Noguera-Julian A, Vila J, Vila A, Valls A, Sánchez E, Jiménez R, Fortuny C.

Pediatr Nephrol. 2014 Sep;29(9):1561-6. doi: 10.1007/s00467-014-2814-7. Epub 2014 Apr 16.

PMID:
24733585

Supplemental Content

Support Center